Browse TMEM107

Summary
SymbolTMEM107
Nametransmembrane protein 107
Aliases MGC10744; GRVS638; PRO1268
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein Cell projection, cilium Note=Localizes at the transition zone, a region between the basal body and the ciliary axoneme.
Domain PF14995 Transmembrane protein
Function

Plays a role in cilia formation and embryonic patterning. Requires for normal Sonic hedgehog (Shh) signaling in the neural tube and acts in combination with GLI2 and GLI3 to pattern ventral and intermediate neuronal cell types (By similarity). During ciliogenesis regulates the ciliary transition zone localization of some MKS complex proteins (PubMed:26518474).

> Gene Ontology
 
Biological Process GO:0003002 regionalization
GO:0007389 pattern specification process
GO:0010927 cellular component assembly involved in morphogenesis
GO:0021532 neural tube patterning
GO:0021915 neural tube development
GO:0030031 cell projection assembly
GO:0030326 embryonic limb morphogenesis
GO:0035058 nonmotile primary cilium assembly
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0042384 cilium assembly
GO:0042733 embryonic digit morphogenesis
GO:0044782 cilium organization
GO:0048736 appendage development
GO:0060173 limb development
GO:0060271 cilium morphogenesis
GO:0061512 protein localization to cilium
GO:0097499 protein localization to nonmotile primary cilium
GO:1904491 protein localization to ciliary transition zone
Molecular Function -
Cellular Component GO:0005929 cilium
GO:0031513 nonmotile primary cilium
GO:0035869 ciliary transition zone
GO:0044441 ciliary part
GO:0072372 primary cilium
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTMEM107
Nametransmembrane protein 107
Aliases MGC10744; GRVS638; PRO1268
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TMEM107 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTMEM107
Nametransmembrane protein 107
Aliases MGC10744; GRVS638; PRO1268
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TMEM107 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTMEM107
Nametransmembrane protein 107
Aliases MGC10744; GRVS638; PRO1268
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TMEM107 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3860.0593
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5380.701
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2770.794
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.0060.00628
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.1140.322
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.870.526
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1780.608
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0250.98
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3640.75
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5450.709
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0160.994
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0460.618
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TMEM107 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTMEM107
Nametransmembrane protein 107
Aliases MGC10744; GRVS638; PRO1268
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TMEM107. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTMEM107
Nametransmembrane protein 107
Aliases MGC10744; GRVS638; PRO1268
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TMEM107. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TMEM107.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTMEM107
Nametransmembrane protein 107
Aliases MGC10744; GRVS638; PRO1268
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TMEM107. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTMEM107
Nametransmembrane protein 107
Aliases MGC10744; GRVS638; PRO1268
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TMEM107 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTMEM107
Nametransmembrane protein 107
Aliases MGC10744; GRVS638; PRO1268
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TMEM107 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTMEM107
Nametransmembrane protein 107
Aliases MGC10744; GRVS638; PRO1268
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TMEM107 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.